LSTA
Lisata Therapeutics, Inc. (LSTA) Economic Moat Analysis (2026)
Overall Score
Pricing Power
Gross margin remains very high at 95%, but the company’s extreme revenue multiple and deeply negative operating margins indicate little evidence of durable pricing power translating into profits.
Price-to-sales of 152.1x suggests the market is valuing future growth heavily, not current monetization strength.
Cost Advantage
Operating expenses remain far above revenue, with SG&A at 116.4% of revenue and R&D at 48.8%, showing no current cost advantage.
Negative operating cash flow and free cash flow reinforce that the business is not yet operating with structural cost efficiency.
Switching Costs
No evidence in the financials of customer lock-in or recurring revenue durability; the company still posts very weak profitability and cash generation.
Receivables turnover of 0.5x and a 730-day operating cycle suggest weak commercial efficiency rather than sticky customer relationships.
Network Effects
The available metrics do not show any network-effect flywheel or scale-driven monetization advantage.
Persistently negative margins and cash flow imply the business is not yet benefiting from self-reinforcing user or ecosystem growth.
Intangible Assets
R&D intensity is high at 48.8% of revenue, but the financials do not yet show monetization of proprietary assets or IP.
The company’s profitability remains deeply negative, so any intangible advantage is not currently translating into economic returns.
Efficient Scale
There is no sign of efficient-scale economics in the current results; returns on capital remain deeply negative and revenue productivity is extremely low.
The business appears too small and unprofitable to demonstrate a moat from scale economies at this stage.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lisata Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

